Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.38 USD | -3.50% | -3.70% | -14.34% |
04-16 | Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration | MT |
04-16 | Transcript : Precision BioSciences, Inc. - Special Call |
Sales 2024 * | 21.17M 1.69B | Sales 2025 * | 21.46M 1.72B | Capitalization | 64.87M 5.19B |
---|---|---|---|---|---|
Net income 2024 * | -50M -4B | Net income 2025 * | -60M -4.8B | EV / Sales 2024 * | 0.12 x |
Net cash position 2024 * | 62.43M 5B | Net cash position 2025 * | 135M 10.8B | EV / Sales 2025 * | -3.26 x |
P/E ratio 2024 * |
-1.27
x | P/E ratio 2025 * |
-2.01
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Precision BioSciences, Inc.
1 day | -3.50% | ||
1 week | -3.70% | ||
Current month | -30.83% | ||
1 month | -26.43% | ||
3 months | -13.53% | ||
6 months | +7.63% | ||
Current year | -14.34% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Amoroso
CEO | Chief Executive Officer | 46 | 14/10/21 |
Jeff Smith
FOU | Founder | - | 25/01/06 |
John Kelly
DFI | Director of Finance/CFO | 57 | 13/10/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kevin Buehler
CHM | Chairman | 66 | 07/11/19 |
Geno Germano
BRD | Director/Board Member | 63 | 09/03/20 |
Director/Board Member | 75 | 05/11/21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.16% | 2 M€ | -25.75% | ||
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 9.38 | -3.50% | 28,994 |
25/04/24 | 9.72 | -1.02% | 21,921 |
24/04/24 | 9.82 | -4.01% | 33,626 |
23/04/24 | 10.23 | +5.68% | 31,106 |
22/04/24 | 9.68 | -0.62% | 47,192 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
- Stock Market
- Equities
- DTIL Stock